Credits: Canva
Anyone who has ever cared for a child with painful ear infection would know how difficult those days and nights are when the child is unable to be at peace. Relief often takes time, and sometimes doe not at all come. However, ear infections in toddlers are quite a common phenomenon, and are often stubborn. Children can also develop resistance to standard antibiotics due to its constant use. This means the infection can return even after days of treatment.
Researchers at Cornell University may have found it. There is an alternative that exist- a single-dose, topical antibiotic gel that could simplify treatment and reduce recuring infections.
While earlier, the doctors have relief on oral antibiotics, which also had side effects like upset stomachs, and year infections. This new method delivers medicines directly in the infected ear. Doctors predict this to be game changer, especially for children who struggle with oral medication.
However, the challenge is that most ear infections affect the middle ear, which sits behind the eardrum. This is the barrier that most drugs cannot cross. This is where the new approach and its innovation comes into play.
The research is led by Rong Yang, assistant professor of chemical and biomolecular engineering, and the Cornell team have found their way around. They have packaged the antibiotic ciprofloxacin into microscopic delivery vehicles called liposomes. These are tiny, bubble-like structure which are used to carry drugs to hard-to-reach parts of the body.
These liposomes are negatively charged, which then helps them to bind better to the ear tissue. They are then incorporated into a gel-like salve, which is then applied directly to the eardrum.
In lab tests on chinchillas — whose ears closely resemble human ears — the results were impressive. The infections cleared up within 24 hours of a single application. Over the next week, no signs of the infection returned, and there was no inflammation in the eardrums.
The study, recently published in ACS Nano, marks a significant step toward making ear infection treatment faster, more effective, and less taxing on children and their families.
Despite these promising results, researchers caution that what works in animals doesn’t always translate directly to humans. Other versions of the gel tested on chinchillas were less effective, and much more work remains before this treatment can be approved for children.
Still, the potential is real. "A single-dose treatment for middle ear infections represents a significant step forward," Yang said in a statement. "It could reduce the burden on families and improve outcomes for young children."
She added that moving from lab tests to clinical trials is the next key step: "It has the potential to improve patient compliance, reduce antibiotic resistance, and ultimately transform how children receive antibiotics."
Credits: AP
For two decades, American-led investment through programs like PEPFAR (The U.S. President’s Emergency Plan for AIDS Relief) has helped slash global AIDS-related deaths to their lowest levels in over 30 years. But this progress is now at serious risk. A sudden and sweeping withdrawal of U.S. foreign aid has triggered what the United Nations is calling a “systemic shock” to HIV response systems around the world.
According to a new UNAIDS report, if the funding gap remains unresolved, the world could see more than 4 million additional AIDS-related deaths and 6 million new HIV infections by 2029. The consequences are already visible — health facilities shuttered, supply chains broken, testing and treatment disrupted, and clinics in sub-Saharan Africa forced to halt vital HIV services.
In January, President Trump abruptly suspended all foreign aid and took steps to dismantle the U.S. Agency for International Development (USAID). That move wiped out $4 billion in pledged HIV funding for 2025, including the backbone funding for programs in Africa, Asia, and Latin America.
Launched in 2003 under President George W. Bush, PEPFAR has been called the largest commitment by any country to fight a single disease. Since its inception, it has supported HIV testing for more than 84 million people and treatment for over 20 million. Countries like Nigeria, where 99.9% of the national HIV prevention budget was supported by PEPFAR, are now facing catastrophic disruption.
Andrew Hill, an HIV researcher at the University of Liverpool, criticized the U.S. government's abrupt move: “Any responsible government would have given advance warning so countries could plan,” he said. “Instead, patients were stranded, and clinics closed overnight.”
The fallout from the funding cut is widespread. UNAIDS has reported large-scale impacts: medical facilities without staff, vital medications running out, and HIV testing and surveillance collapsing in several regions.
The U.S. was the main funder of HIV data systems across Africa — from patient records to electronic surveillance systems. With that infrastructure now unsupported, global experts worry that tracking and controlling the spread of HIV is about to get significantly harder.
“Without reliable data about how HIV is spreading, it will be incredibly hard to stop it,” said Dr. Chris Beyrer, director of the Global Health Institute at Duke University.
What makes this funding crisis even more tragic is the timing. Just as the world reaches the brink of a possible HIV breakthrough, it may be losing the means to distribute it.
Gilead’s new injectable drug, Yeztugo, was approved by the U.S. FDA last month. Clinical trials suggest it is 100% effective at preventing HIV when administered twice a year. At a launch event, South Africa’s Health Minister, Dr. Aaron Motsoaledi, emphasized its potential: “We will move mountains and rivers to make sure every adolescent girl who needs it will get it.”
Yet many countries may never see the drug. Gilead has promised low-cost generic versions for 120 poorer countries, but has notably excluded most of Latin America — where HIV rates are increasing, even if they are lower overall.
Peter Maybarduk, director at Public Citizen, called it a “threshold moment” in the fight against AIDS. But he fears it will be squandered: “We could be ending AIDS. Instead, the U.S. is abandoning the fight.”
Sub-Saharan Africa accounts for roughly half of all new HIV infections globally. Even before the U.S. pullback, access to care and medication in the region was fragile and uneven.
Dr. Tom Ellman, with Doctors Without Borders in South Africa, put it bluntly: “There’s nothing we can do that will protect these countries from the sudden, vicious withdrawal of support from the U.S.”
While some nations have begun building domestic HIV response programs, the gap left by the U.S. is simply too wide. Prevention campaigns are faltering, awareness efforts have stalled, and many community-based initiatives have been forced to shut down or drastically scale back.
In 2004, AIDS claimed nearly 2 million lives globally. By 2024, that number had dropped to around 630,000, largely thanks to international funding and collaborative programs. But UNAIDS warns that without renewed support, these hard-won gains could unravel rapidly.
Geopolitical shifts, ongoing wars, and climate-related disruptions are already putting pressure on global health cooperation. The loss of the U.S. as a stabilizing force in the HIV response leaves many questioning what’s next.
The most vulnerable — young women, children, LGBTQ+ communities, and those in poverty — stand to lose the most.
UNAIDS and other global health leaders are urging the international community to step up. Whether through restoring U.S. funding or rallying alternative donors, a coordinated response is essential. Experts are also calling for pharmaceutical companies like Gilead to expand access and reduce costs, ensuring that breakthroughs don’t become tools of inequality.
The global AIDS fight is far from over. In fact, this moment may determine whether it's won or lost.
If nothing changes, the consequences are clear: millions of lives in the balance, and a public health crisis reborn from neglect.
Credits: Canva
Respiratory Syncytial Virus (RSV) might sound like a complicated medical term, but for millions of families across the globe, especially in India, it’s become a harsh and deadly reality. Though often mistaken for a seasonal cold, RSV is the leading cause of lower respiratory tract infections in children under five—and it’s killing thousands.
Each year, RSV is linked to approximately 3.6 million hospitalisations and nearly 100,000 deaths in children under five. India, with its annual birth cohort of over 25 million, contributes significantly to this global burden. In 2024 alone, 2,360 infant deaths in just three cities—Bengaluru, Kolkata, and Mumbai—were reported as RSV-related and experts believe this is only the tip of the iceberg.
Respiratory Syncytial Virus (RSV) is a highly contagious virus that infects the respiratory tract, particularly affecting the nose, throat, lungs, and breathing passages. It spreads through droplets from an infected person via coughing, sneezing, or even kissing. Contaminated surfaces like cribs, toys, or door handles can also carry the virus for hours.
RSV is so widespread that almost every child is infected by it at least once by the age of two. While it might look like a regular cold in some cases, in many infants, RSV progresses rapidly into bronchiolitis or pneumonia—both of which can be life-threatening.
Shockingly, around 80% of children under two who are hospitalised with RSV have no prior risk factors. Which means even full-term, healthy infants are at risk.
Despite being a notifiable disease in India for nearly five decades, RSV is severely under-tested. Dr. Vasant M. Khalatkar, National President of the IAP, pointed out that RSV testing in India often happens only when a full-blown outbreak occurs—like the one seen in Kolkata earlier this year.
“People still treat it as a bad cold,” Dr. Khalatkar said at a Bengaluru roundtable on RSV. “But for infants, RSV can escalate within three days from mild symptoms to severe respiratory complications that demand hospitalisation, oxygen support, or ventilation.”
A lack of awareness among caregivers and healthcare providers, combined with limited diagnostic access, has created a dangerous information gap—one that continues to cost young lives.
Dr. Bhavesh Kotak, Head of Medical Affairs at Dr Reddy’s, underscored that RSV accounts for 63% of all acute respiratory infections in young children, citing WHO-backed data. In India, this means a significant share of childhood respiratory hospitalisations are linked to RSV, especially during monsoon and early winter months.
RSV doesn’t discriminate—children from all socio-economic backgrounds, including those born full-term, are frequently hospitalised. Unlike in high-income countries that have early preventive care and widespread immunisation, India still struggles with timely diagnosis and access to life-saving tools.
The most promising development in the fight against RSV is the introduction of long-acting monoclonal antibodies (mAbs) and maternal vaccines—both backed by WHO and CDC guidelines.
Palivizumab, available for several years, has been used in high-risk infants but requires monthly doses throughout the RSV season.
Nirsevimab, a new and highly effective long-acting antibody, offers season-long protection with a single dose and is now being rolled out globally, including in India.
Additionally, the WHO recommends maternal vaccination with Abrysvo® during weeks 32–36 of pregnancy to protect babies after birth. This approach helps infants develop passive immunity and dramatically lowers their risk of severe RSV disease.
Dr. Khalatkar emphasised that immunisation—when paired with awareness and access—can significantly reduce RSV-related hospitalisations and deaths.
Let’s break this down: India has 25 million newborns annually. Without preventive strategies, even a small percentage developing severe RSV means hundreds of thousands of hospitalisations and thousands of avoidable deaths. Unlike high-income countries, India faces several hurdles:
This gap is precisely where action is most needed.
According to the Centers for Disease Control and Prevention (CDC), RSV is the leading cause of hospitalisation in U.S. children under one year. RSV also causes 100,000–160,000 hospitalisations annually in U.S. adults aged 60 and older. The CDC recommends:
If adopted effectively in India, similar immunisation protocols could transform RSV management—especially for the first 6 months of an infant’s life, when vulnerability is highest.
Simple precautions like handwashing, covering coughs, and disinfecting surfaces are useful but insufficient in high-burden, high-transmission environments—particularly for babies under 12 months. Experts unanimously agree that preventive immunisation is the game-changer.
WHO’s Dr. Kate O’Brien summed it up clearly: “The RSV immunisation products can transform the fight against severe RSV disease, dramatically reduce hospitalisations and deaths, and save many infant lives globally.”
RSV is no longer a vague acronym in pediatric medicine—it’s a clear and present danger to child health in India and worldwide. And while developed nations have made strides in RSV prevention, India remains at a critical crossroad.
Credits: Freepik
The CDC has just delivered a reality check revealing over 8.4 million American teens aged 12 to 17—roughly one in three—are prediabetic. That’s 32.7% of U.S. adolescents showing early signs of blood sugar trouble that could spiral into full-blown type 2 diabetes. And this isn’t just about elevated glucose levels. This is a window into a much larger crisis: preventable chronic illness silently growing among kids who haven’t even finished high school.
“This is a wake-up call,” says Dr. Christopher Holliday, the CDC’s Director for Diabetes Translation, pointing to the massive and preventable health burden the country now faces. The warning is clear—teen health is declining, and unless there’s a nationwide shift in how we approach diet, movement, stress, and sleep, things are going to get worse before they get better.
Prediabetes means your blood sugar levels are elevated but not high enough for a diagnosis of type 2 diabetes. It’s like standing at the edge of a cliff—you’re not falling yet, but you’re dangerously close.
During puberty, a teen’s body undergoes hormonal shifts that can naturally interfere with how well insulin works. According to Yale Medicine, this makes adolescence a critical window for diabetes risk to take root. Without intervention, prediabetes can evolve into type 2 diabetes, paving the way for serious health complications including kidney damage, stroke, and cardiovascular disease.
Type 2 diabetes itself is a long-term condition where the body struggles to use insulin properly. Over time, blood sugar builds up in the bloodstream and starts damaging tissues and organs. The progression is slow and mostly silent. Many don’t even know they’re prediabetic until symptoms become too obvious to ignore.
The CDC's 2023 data isn’t the first red flag. A 2020 study published in JAMA Pediatrics revealed that the prediabetes rate in teens more than doubled between 1999 and 2018—from 12% to 28%. The latest CDC estimate of 32.7% suggests that the trend hasn’t just continued—it’s accelerating.
What’s even more sobering is how unevenly this crisis affects different groups. Teens living in poverty are significantly more likely to be prediabetic, tied to issues like food insecurity, poor access to healthcare, and systemic inequality. Research from the University of Pittsburgh connects prediabetes risk with lack of insurance and household incomes below 130% of the federal poverty level.
And there’s a racial disparity too: African American, Hispanic/Latino, American Indian, Alaska Native, Pacific Islander, and some Asian American communities carry a disproportionately high burden of prediabetes and type 2 diabetes.
There’s no single culprit. But a combination of poor nutrition, sedentary habits, limited access to safe outdoor spaces, ultra-processed food marketing, and rising stress levels among adolescents are all playing a role.
Let’s be honest—the modern American teen lifestyle is working against metabolic health. Fast food is cheap and available everywhere. Physical education has been reduced or eliminated in many schools. Screen time has skyrocketed, especially since the pandemic. Many families, particularly those struggling financially, don’t have the luxury of prioritizing healthy eating or gym memberships.
Add to that a healthcare system that often fails to screen for prediabetes in young people, and you’ve got a perfect storm.
Yes—and this is where the good news comes in. According to the American Diabetes Association, prediabetes can be reversed or delayed through sustainable, everyday choices. Dr. Holliday emphasizes that “simple life changes—like healthy eating and staying active—can make a big difference.” Here’s what makes the biggest impact:
These aren’t drastic changes. In fact, experts say even modest shifts in habits can dramatically reduce risk.
One of the most troubling aspects of prediabetes is how few people know they have it. Among American adults, more than 80% of those with prediabetes are unaware. And in teens, the lack of screening and routine checkups makes it even easier for warning signs to go unnoticed.
The key now is early intervention. Pediatricians, schools, and families need to be having these conversations. Blood sugar testing should be routine for at-risk teens. And public health efforts must prioritize communities most affected—those dealing with food deserts, high poverty rates, and systemic barriers to care.
This isn’t just a family-level issue. It’s a national health crisis that demands systemic action. Here’s what needs to shift:
Healthcare policy: Expand routine screenings for teens, especially in underserved populations.
Food access programs: Subsidize fresh produce in low-income areas and restrict junk food marketing to kids.
School reforms: Reinstate physical education, revamp cafeteria offerings, and make mental health counseling widely available.
Community initiatives: Fund safe recreational spaces, after-school sports, and education campaigns targeting families and caregivers.
The fact that over 8 million U.S. teens are already prediabetic should stop us in our tracks but this isn’t a lost cause. Prediabetes doesn’t have to become diabetes. The road ahead doesn’t require miracles—just smarter choices, better systems, and the will to prioritize adolescent health. If the U.S. can treat this data as the urgent warning it is, we can flip the script on youth diabetes before it's too late.
© 2024 Bennett, Coleman & Company Limited